We hypothesized that the higher, avidity-driven binding affinity for the cancer antigens of the parental PSMA and MUC16 antibodies used to generate these bsAbs would block the target arm’s binding of the bsAbs in a dose-dependent manner. The gene discussed is FOLH1; the disease is cancer.